Suchergebnisse - "B7-H1 Antigen therapeutic use"

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Autoren: Gilberto de Castro Iveta Kudaba Yi-Long Wu et al.

Weitere Verfasser: Gilberto de Castro Iveta Kudaba Yi-Long Wu et al.

Quelle: J Clin Oncol

Schlagwörter: 0301 basic medicine, cancer patient, leukocyte count, vomiting, drug safety, Lung Neoplasms, CD274 protein, human, clinical outcome, Carboplatin / therapeutic use, B7-H1 Antigen, lung tumor, Carboplatin, paclitaxel, 0302 clinical medicine, infusion related reaction, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, advanced cancer, brain metastasis, pemetrexed, antineoplastic agent, comparative study, progression free survival, adult, anaplastic lymphoma kinase, nausea, anemia, Lung Neoplasms* / drug therapy, 3. Good health, ErbB Receptors, aged, epidermal growth factor, female, carboplatin, Non-Small-Cell Lung* / drug therapy, disease severity, pembrolizumab, never smoker, Paclitaxel / therapeutic use, current smoker, ex-smoker, Paclitaxel, area under the curve, overall survival, Pemetrexed / therapeutic use, adverse drug reaction, maintenance therapy, programmed death ligand 1 tumor proportion score, Pemetrexed, intention to treat analysis, Article, cancer chemotherapy, multiple cycle treatment, histology, skin manifestation, 03 medical and health sciences, male, death, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, cancer combination chemotherapy, cancer radiotherapy, follow up, neutropenia, oncological parameters, Humans, controlled study, human, decreased appetite, Receptor Protein-Tyrosine Kinases / therapeutic use, non small cell lung cancer, ECOG Performance Status, neutrophil count, Carcinoma, response evaluation criteria in solid tumors, treatment response, Receptor Protein-Tyrosine Kinases, protein tyrosine kinase, constipation, platelet count, alopecia, major clinical study, hypophysitis, programmed death 1 ligand 1, drug efficacy, CLINICAL TRIAL UPDATES, B7-H1 Antigen / therapeutic use, randomized controlled trial, fatigue, hypothyroidism, epidermal growth factor receptor, first-line treatment

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36306479
https://hdl.handle.net/20.500.12831/12965
https://doi.org/10.1200/jco.21.02885

Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy

Autoren: Kyung Hwan, Kim Hongryull, Pyo Hoyoung, Lee et al.

Weitere Verfasser: Kyung Hwan, Kim Hongryull, Pyo Hoyoung, Lee et al.

Quelle: International Journal of Radiation Oncology*Biology*Physics. 113:415-425

Schlagwörter: 0301 basic medicine, 0303 health sciences, Lung Neoplasms, Non-Small-Cell Lung, Carcinoma, Programmed Cell Death 1 Receptor, Chemoradiotherapy, CD8-Positive T-Lymphocytes, B7-H1 Antigen, 3. Good health, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, B7-H1 Antigen / therapeutic use, Carcinoma, Non-Small-Cell Lung, Humans, Lymphocytes, Tumor-Infiltrating, Immune Checkpoint Inhibitors, Chemoradiotherapy / methods

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35150786

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Autoren: Shitara, K. Ozguroglu, M. Bang, Y-J. et al.

Weitere Verfasser: Shitara, K. Ozguroglu, M. Bang, Y-J. et al.

Quelle: Annals of Oncology. 32:1127-1136

Schlagwörter: 0301 basic medicine, tumor mutational burden, Esophageal Neoplasms, Paclitaxel, Esophageal Neoplasms* / drug therapy, Benefit, Adenocarcinoma, Adenocarcinoma* / genetics, NSCLC, chemotherapy, Antibodies, Monoclonal, Humanized, Antibodies, B7-H1 Antigen, Adenocarcinoma* / drug therapy, 03 medical and health sciences, 3211 Oncology and carcinogenesis, Monoclonal, Humanized / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Tumor Mutational Burden, Humans, BENEFIT, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, PEMBRO, gastroesophageal adenocarcinoma, 0303 health sciences, Science & Technology, Ctla-4 Blockade, gastric cancer, CTLA-4 BLOCKADE, 3202 Clinical sciences, TISSUE TMB TTMB, PD-1 BLOCKADE, 3. Good health, Oncology, B7-H1 Antigen / therapeutic use, Pd-1 Blockade, Chemo, TUMOR MUTATIONAL BURDEN, CHEMO, Esophageal Neoplasms* / genetics, pembrolizumab, Paclitaxel / therapeutic use, Life Sciences & Biomedicine

Dateibeschreibung: application/pdf

Zugangs-URL: http://www.annalsofoncology.org/article/S0923753421020287/pdf
https://pubmed.ncbi.nlm.nih.gov/34082019
https://research.unipg.it/handle/11391/1493908
https://europepmc.org/article/MED/34082019
https://avesis.istanbul.edu.tr/yayin/2049990f-daa5-40d7-a024-1f3c5cf3e20a/molecular-determinants-of-clinical-outcomes-with-pembrolizumab-versus-paclitaxel-in-a-randomized-open-label-phase-iii-trial-in-patients-with-gastroesophageal-adenocarcinoma
https://snucm.elsevierpure.com/en/publications/molecular-determinants-of-clinical-outcomes-with-pembrolizumab-ve
https://pubmed.ncbi.nlm.nih.gov/34082019/
https://www.ncbi.nlm.nih.gov/pubmed/34082019
https://lirias.kuleuven.be/handle/123456789/680656
https://doi.org/10.1016/j.annonc.2021.05.803

Prognostic stratification of oropharyngeal cancer patients in a betel nut chewing and low HPV area

Autoren: Huai-Pao Lee Ching-Chih Lee

Quelle: J Otolaryngol Head Neck Surg
Journal of Otolaryngology-Head and Neck Surgery, Vol 52, Iss 1, Pp 1-9 (2023)

Schlagwörter: ErbB Receptors [MeSH], Oropharyngeal Neoplasms/pathology [MeSH], Papillomavirus Infections/pathology [MeSH], Epidermal growth factor receptor (EGFR), p16, Aged [MeSH], Humans [MeSH], Middle Aged [MeSH], B7-H1 Antigen/therapeutic use [MeSH], Mastication [MeSH], Prediction, Neoplasm Staging [MeSH], Survival, Human Papillomavirus Viruses [MeSH], Prognosis [MeSH], Oropharyngeal cancer, Original Research Article, Areca/adverse effects [MeSH], RD1-811, Papillomavirus Infections, Human Papillomavirus Viruses, Middle Aged, Prognosis, B7-H1 Antigen, 3. Good health, ErbB Receptors, Oropharyngeal Neoplasms, Humans, Mastication, Surgery, Areca, Aged, Neoplasm Staging

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37081578
https://doaj.org/article/c4925665e31645299f2b01a4133c031a
https://repository.publisso.de/resource/frl:6477646

First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.

Autoren: De Caluwe, Alex Romano, Emanuela Poortmans, Philip et al.

Quelle: Journal for ImmunoTherapy of Cancer, 11 (12

Schlagwörter: Sciences bio-médicales et agricoles, Humans, Adult, Middle Aged, Aged, Female, Breast Neoplasms -- drug therapy -- radiotherapy, B7-H1 Antigen -- therapeutic use, Radiosurgery -- methods, Prognosis, Combined Modality Therapy, Adenosine, Breast Neoplasms, Immunotherapy, Radiotherapy

Dateibeschreibung: 1 full-text file(s): application/pdf

Relation: uri/info:pmid/38056900; uri/info:scp/85179025470; uri/info:pmcid/PMC10711977; https://dipot.ulb.ac.be/dspace/bitstream/2013/366859/3/e007279.full.pdf

Verfügbarkeit: http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/366859
https://dipot.ulb.ac.be/dspace/bitstream/2013/366859/3/e007279.full.pdf

Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial

Weitere Verfasser: Jung-Yun Lee Byoung-Gie Kim Jae-Weon Kim et al.

Schlagwörter: Antineoplastic Combined Chemotherapy Protocols / therapeutic use, B7-H1 Antigen* / therapeutic use, Biomarkers, Carcinoma, Ovarian Epithelial / drug therapy, Drug Resistance, Neoplasm, Female, Humans, Ovarian Neoplasms* / pathology, Paclitaxel, Topotecan / adverse effects, Biomarker, Immunotherapy, Molecular Targeted Therapy, Ovarian Cancer, Platinum Resistant

Relation: JOURNAL OF GYNECOLOGIC ONCOLOGY; J01428; https://ir.ymlib.yonsei.ac.kr/handle/22282913/191687; T202205067

Verfügbarkeit: https://ir.ymlib.yonsei.ac.kr/handle/22282913/191687
https://doi.org/10.3802/jgo.2022.33.e45

First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial

Autoren: Alex De Caluwe Emanuela Romano Philip Poortmans et al.

Quelle: J Immunother Cancer
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Journal for ImmunoTherapy of Cancer

Schlagwörter: Clinical/Translational Cancer Immunotherapy, Adult, Radiosurgery -- methods, Breast Neoplasms -- drug therapy -- radiotherapy, Adenosine, Radiotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Breast Neoplasms, Sciences bio-médicales et agricoles, B7-H1 Antigen -- therapeutic use, Middle Aged, Radiosurgery, Prognosis, Combined Modality Therapy, B7-H1 Antigen, 3. Good health, Humans, Female, Immunotherapy, Human medicine, 10. No inequality, RC254-282, Aged

Dateibeschreibung: 1 full-text file(s): application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38056900
https://doaj.org/article/a5ee6654546a4d7e98521bceca85490a
https://hdl.handle.net/10067/2021080151162165141
https://repository.uantwerpen.be/docstore/d:irua:21267

Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.

Weitere Verfasser: College of Medicine Yonsei Biomedical Research Center Jong Hoon Kim et al.

Schlagwörter: Adjuvants, Immunologic, Aminoquinolines, Animals, B7-H1 Antigen/pharmacology, B7-H1 Antigen/therapeutic use, Humans, Inflammation/metabolism, Interleukin-17/metabolism, Mice, Inbred C57BL, Programmed Cell Death 1 Receptor/metabolism, Psoriasis/chemically induced, Psoriasis/drug therapy, Psoriasis/metabolism, Recombinant Proteins/pharmacology, Recombinant Proteins/therapeutic use, Skin/drug effects, Skin/metabolism, T-Lymphocyte Subsets/metabolism, IL-17A, Psoriasis, T cell, programmed cell death 1, programmed cell death ligand 1

Dateibeschreibung: 1466~1476

Relation: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY; J01228; https://ir.ymlib.yonsei.ac.kr/handle/22282913/147037; http://www.sciencedirect.com/science/article/pii/S0091674916000221; T201601970; 47069

Verfügbarkeit: https://ir.ymlib.yonsei.ac.kr/handle/22282913/147037
https://doi.org/10.1016/j.jaci.2015.11.021
http://www.sciencedirect.com/science/article/pii/S0091674916000221